---
title: "In vitro activity of gepotidacin vs Neisseria gonorrhoeae isolates from the EAGLE-1 trial"
id: "pubmed-42841733"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42841733"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42841733/"
doi: "10.1128/aac.00752-26"
published_at: "2026-11-04T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# In vitro activity of gepotidacin vs Neisseria gonorrhoeae isolates from the EAGLE-1 trial
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42841733
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42841733/)
- **DOI:** [10.1128/aac.00752-26](https://doi.org/10.1128%2Faac.00752-26)
- **Published At:** 2026-11-04T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- The EAGLE-1 phase III clinical trial supplied 408 baseline urogenital isolates recovered from 406 patients for microbiological analysis. - Investigators performed agar dilution minimum inhibitory concentration (MIC) testing following Clinical and Laboratory Standards Institute (CLSI) methods; all isolates were molecularly characterized. - All isolates were reported as susceptible to **ceftriaxone** by the study team. - **Gepotidacin** MICs across the collection ranged from ≤0.06 to 2 µg/mL, with an MIC50 of 0.25 µg/mL and an MIC90 of 0.5 µg/mL. - Using FDA interpretive criteria (≤1 µg/mL susceptible; 2 µg/mL intermediate; ≥4 µg/mL resistant), 99% of isolates were classified as susceptible to **gepotidacin**, 1% intermediate, and none resistant. - Susceptibility to gepotidacin remained high across phenotypic and genotypic resistance subsets; the authors reported preserved in vitro activity against drug-resistant **Neisseria gonorrhoeae** phenotypes and genotypes recovered during EAGLE-1. - The study is registered as ClinicalTrials.gov NCT04010539. - Authors disclosed employment by and financial equities in GSK for all listed contributors.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42841733/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42841733%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42841733/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42841733/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42841733/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42841733/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42841733/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42841733/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42841733%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42841733%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42841733/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42841733/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42841733/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42841733/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Atypon full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--journals.asm.org-pb-assets-pubmed-pubmed_ASMJ_OA.png) Atypon ](https://journals.asm.org/doi/10.1128/aac.00752-26?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed "See full text options at Atypon") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42841733/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42841733/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42841733/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42841733/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42841733/#conflict-of-interest) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42841733/#similar) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42841733/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42841733/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42841733/#substances) * [ Associated data ](https://pubmed.ncbi.nlm.nih.gov/42841733/#supplemental-data) * [Related information](https://pubmed.ncbi.nlm.nih.gov/42841733/#related-links) * [ Grants and funding ](https://pubmed.ncbi.nlm.nih.gov/42841733/#grants) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42841733/#linkout) Title & authors Abstract Conflict of interest statement Similar articles Publication types MeSH terms Substances Associated data Related information Grants and funding LinkOut - more resources Clinical Trial Antimicrob Agents Chemother Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antimicrob+Agents+Chemother%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Antimicrob+Agents+Chemother%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42841733/) . 2026 Nov 4;70(11):e0075226. doi: 10.1128/aac.00752-26. Epub 2026 Oct 7. # _In vitro_ activity of gepotidacin against baseline _Neisseria gonorrhoeae_ phenotypes and genotypes recovered from a clinical trial for uncomplicated urogenital gonorrhea (EAGLE-1) [Charles Jakielaszek](https://pubmed.ncbi.nlm.nih.gov/?term=Jakielaszek+C&cauthor_id=42841733)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42841733/#full-view-affiliation-1 "Infectious Diseases Research, GSK, Collegeville, Pennsylvania, USA."), [William Flight](https://pubmed.ncbi.nlm.nih.gov/?term=Flight+W&cauthor_id=42841733)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42841733/#full-view-affiliation-2 "Infectious Diseases Research, GSK, London, United Kingdom."), [Dan Lythgoe](https://pubmed.ncbi.nlm.nih.gov/?term=Lythgoe+D&cauthor_id=42841733)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42841733/#full-view-affiliation-3 "Biostatistics, GSK, Stevenage, United Kingdom."), [Caroline Perry](https://pubmed.ncbi.nlm.nih.gov/?term=Perry+C&cauthor_id=42841733)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42841733/#full-view-affiliation-1 "Infectious Diseases Research, GSK, Collegeville, Pennsylvania, USA."), [Nicole E Scangarella-Oman](https://pubmed.ncbi.nlm.nih.gov/?term=Scangarella-Oman+NE&cauthor_id=42841733)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42841733/#full-view-affiliation-1 "Infectious Diseases Research, GSK, Collegeville, Pennsylvania, USA.") Affiliations Expand ### Affiliations * 1 Infectious Diseases Research, GSK, Collegeville, Pennsylvania, USA. * 2 Infectious Diseases Research, GSK, London, United Kingdom. * 3 Biostatistics, GSK, Stevenage, United Kingdom. * PMID: **42841733** * DOI: [ 10.1128/aac.00752-26 ](https://doi.org/10.1128/aac.00752-26) Free article Item in Clipboard Clinical Trial # _In vitro_ activity of gepotidacin against baseline _Neisseria gonorrhoeae_ phenotypes and genotypes recovered from a clinical trial for uncomplicated urogenital gonorrhea (EAGLE-1) Charles Jakielaszek et al. Antimicrob Agents Chemother. 2026. Free article Show details Display options Display options Format Abstract PubMed PMID Antimicrob Agents Chemother Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antimicrob+Agents+Chemother%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Antimicrob+Agents+Chemother%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42841733/) . 2026 Nov 4;70(11):e0075226. doi: 10.1128/aac.00752-26. Epub 2026 Oct 7. ### Authors [Charles Jakielaszek](https://pubmed.ncbi.nlm.nih.gov/?term=Jakielaszek+C&cauthor_id=42841733)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42841733/#short-view-affiliation-1 "Infectious Diseases Research, GSK, Collegeville, Pennsylvania, USA."), [William Flight](https://pubmed.ncbi.nlm.nih.gov/?term=Flight+W&cauthor_id=42841733)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42841733/#short-view-affiliation-2 "Infectious Diseases Research, GSK, London, United Kingdom."), [Dan Lythgoe](https://pubmed.ncbi.nlm.nih.gov/?term=Lythgoe+D&cauthor_id=42841733)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42841733/#short-view-affiliation-3 "Biostatistics, GSK, Stevenage, United Kingdom."), [Caroline Perry](https://pubmed.ncbi.nlm.nih.gov/?term=Perry+C&cauthor_id=42841733)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42841733/#short-view-affiliation-1 "Infectious Diseases Research, GSK, Collegeville, Pennsylvania, USA."), [Nicole E Scangarella-Oman](https://pubmed.ncbi.nlm.nih.gov/?term=Scangarella-Oman+NE&cauthor_id=42841733)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42841733/#short-view-affiliation-1 "Infectious Diseases Research, GSK, Collegeville, Pennsylvania, USA.") ### Affiliations * 1 Infectious Diseases Research, GSK, Collegeville, Pennsylvania, USA. * 2 Infectious Diseases Research, GSK, London, United Kingdom. * 3 Biostatistics, GSK, Stevenage, United Kingdom. * PMID: **42841733** * DOI: [ 10.1128/aac.00752-26 ](https://doi.org/10.1128/aac.00752-26) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract There is an urgent need for novel antimicrobials to treat multidrug-resistant strains of _Neisseria gonorrhoeae_. In a phase III trial (EAGLE-1), gepotidacin, a first-in-class triazaacenaphthylene antibacterial, demonstrated non-inferiority to ceftriaxone plus azithromycin as measured by microbiological success for the treatment of uncomplicated urogenital gonorrhea. Here, we assessed the _in vitro_ activity of gepotidacin against key _N. gonorrhoeae_ drug-resistant phenotypes and genotypes from EAGLE-1. There were 408 baseline urogenital isolates recovered from 406 patients during the EAGLE-1 study. Agar dilution minimum inhibitory concentration (MIC) susceptibility testing was performed according to Clinical and Laboratory Standards Institute (CLSI) guidelines, and all isolates were molecularly characterized. All of the isolates were susceptible to ceftriaxone. All isolates had gepotidacin MICs of ≤2 µg/mL, with values ranging from ≤0.06 to 2 µg/mL; MIC50, 0.25 µg/mL, and MIC90, 0.5 µg/mL. As defined by the Food and Drug Administration (FDA) breakpoints and interpretive criteria (MIC breakpoints of ≤1 µg/mL [susceptible]; 2 µg/mL [intermediate]; and ≥4 µg/mL [resistant]), 99% of the study isolates were susceptible to gepotidacin, 1% were intermediate, and no isolates were resistant. Susceptibility percentages remained high across resistance phenotypes and genotypes. These findings support the _in vitro_ activity of gepotidacin against the _N. gonorrhoeae_ isolates, including drug-resistant phenotypes and genotypes, recovered in the EAGLE-1 clinical study.CLINICAL TRIALSThis study is registered with ClinicalTrials.gov as [NCT04010539](http://clinicaltrials.gov/show/NCT04010539 "See in ClinicalTrials.gov"). **Keywords:** EAGLE-1; Neisseria gonorrhoeae; antimicrobial; antimicrobial activity; clinical trial; genotype; gepotidacin; in vitro; phenotype; uncomplicated urogenital gonorrhea. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement C.J., W.F., D.L., C.P., and N.E.S.-O. are employed by GSK and hold financial equities in GSK. ## Similar articles * [ Efficacy and Safety of Gepotidacin as Treatment of Uncomplicated Urogenital Gonorrhea (EAGLE-1): Design of a Randomized, Comparator-Controlled, Phase 3 Study. ](https://pubmed.ncbi.nlm.nih.gov/37751016/) Perry CR, Scangarella-Oman NE, Millns H, Flight W, Gatsi S, Jakielaszek C, Janmohamed S, Lewis DA.Perry CR, et al.Infect Dis Ther. 2023 Sep;12(9):2307-2320. doi: 10.1007/s40121-023-00862-6. Epub 2023 Sep 26.Infect Dis Ther. 2023.PMID: 37751016Free PMC article. * [ High in vitro activity of the novel antimicrobial gepotidacin against Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021-24. ](https://pubmed.ncbi.nlm.nih.gov/41400870/) Ahlstrand J, Maatouk I, Doanh LH, Girdthep N, Golparian D, Heng LS, Hoffman I, Jamoralin MC, Kakooza F, Kittiyaowamarn R, Kyambadde P, Lan PT, Maseko V, Matoga M, Müller E, Nguyen HT, Nguyen TTP, Ouk V, Setiawaty V, Sia SB, Sulaiman V, Virak M, Thuy Nguyen VT, Wi T, Jacobsson S, Unemo M; WHO EGASP Gepotidacin Study Group.Ahlstrand J, et al.J Antimicrob Chemother. 2026 Jan 6;81(1):dkaf452. doi: 10.1093/jac/dkaf452.J Antimicrob Chemother. 2026.PMID: 41400870Free PMC article. * [ Efficacy and _in vitro_ activity of gepotidacin against bacterial uropathogens, including subsets with molecularly characterized resistance mechanisms and genotypes/epidemiological clones, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3). ](https://pubmed.ncbi.nlm.nih.gov/40924012/) Scangarella-Oman NE, Butler DL, Breton J, Brown D, Kasapidis C, Sheets AJ.Scangarella-Oman NE, et al.Antimicrob Agents Chemother. 2025 Oct;69(10):e0163924. doi: 10.1128/aac.01639-24. Epub 2025 Sep 9.Antimicrob Agents Chemother. 2025.PMID: 40924012Free PMC article.Clinical Trial. * [ Dose selection for a phase III study evaluating gepotidacin (GSK2140944) in the treatment of uncomplicated urogenital gonorrhoea. ](https://pubmed.ncbi.nlm.nih.gov/36411033/) Scangarella-Oman NE, Hossain M, Perry CR, Tiffany C, Powell M, Swift B, Dumont EF.Scangarella-Oman NE, et al.Sex Transm Infect. 2023 Feb;99(1):64-69. doi: 10.1136/sextrans-2022-055518. Epub 2022 Nov 21.Sex Transm Infect. 2023.PMID: 36411033Free PMC article.Review. * [ Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea. ](https://pubmed.ncbi.nlm.nih.gov/41964141/) Durham SH, McAllister AK, Chahine EB.Durham SH, et al.Ann Pharmacother. 2026 Oct;60(10):1012-1018. doi: 10.1177/10600280261435593. Epub 2026 Apr 10.Ann Pharmacother. 2026.PMID: 41964141Review. [ See all similar articles ](https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed&from_uid=42841733) ## Publication types * Clinical Trial, Phase III Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Clinical+Trial%2C+Phase+III%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Clinical+Trial%2C+Phase+III) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42841733/) ## MeSH terms * Acenaphthenes* / pharmacology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Acenaphthenes%2Fpharmacology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Acenaphthenes) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42841733/) * Acenaphthenes* / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Acenaphthenes%2Ftherapeutic+use%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Acenaphthenes) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42841733/) * Anti-Bacterial Agents* / pharmacology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Anti-Bacterial+Agents%2Fpharmacology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Anti-Bacterial+Agents) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42841733/) * Anti-Bacterial Agents* / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Anti-Bacterial+Agents%2Ftherapeutic+use%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Anti-Bacterial+Agents) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42841733/) * Azithromycin / pharmacology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Azithromycin%2Fpharmacology%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Azithromycin) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42841733/) * Azithromycin / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Azithromycin%2Ftherapeutic+use%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Azithromycin) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42841733/) * Ceftriaxone / pharmacology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Ceftriaxone%2Fpharmacology%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Ceftriaxone) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42841733/) * Ceftriaxone / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Ceftriaxone%2Ftherapeutic+use%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Ceftriaxone) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42841733/) * Drug Resistance, Multiple, Bacterial / genetics Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Drug+Resistance%2C+Multiple%2C+Bacterial%2Fgenetics%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Drug+Resistance%2C+Multiple%2C+Bacterial) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42841733/) * Female Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Female%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Female) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42841733/) * Genotype Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Genotype%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Genotype) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42841733/) * Gonorrhea* / drug therapy Acti
## Related Clinical Research

- [Pharyngeal Gonorrhea vs Urogenital Strains in Ugandan Men: AMR and Genomic Differences](https://medichelpline.com/clinical-feed/pubmed-42415364.md) (DOI: 10.1093/infdis/jiag353)
- [Multidrug-resistant Salmonella in Fruit Bats and Shared Water Sources in Bangladesh](https://medichelpline.com/clinical-feed/plos-one-22-ecology-and-epidemiology-of-multidrug-resistance-salmonella-in-fruit-bats-and.md)
- [Extragenital Neisseria gonorrhoeae in Argentine transgender women: 9% prevalence, susceptibility,](https://medichelpline.com/clinical-feed/pubmed-42920356.md) (DOI: 10.1177/09564624261495328)
- [EMERGENe: Phylogenetic framework to estimate bacterial trait emergence and expansion](https://medichelpline.com/clinical-feed/medrxiv-1-estimating-emergence-rates-of-epidemiologically-relevant-traits-in-bacteria.md)
- [Genomic epidemiology and emerging antimicrobial resistance in Salmonella Paratyphi A from Australi](https://medichelpline.com/clinical-feed/medrxiv-13-genomic-epidemiology-and-emerging-antimicrobial-resistance-profiles-of.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.